Clinical trials: Renal Allograft Recipients
Kidney Transplant Rejection
PROACT Pilot Trial
Kidney transplantation is considered the best option to treat end-stage kidney disease, but the recipient's immune system may respond with rejection to the transplanted organ, leading to permanent kidney damage and failure.
- Trial name
- NCT06564649
- Testing
- CXCL10 Monitoring at clinical frequency
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Renal Transplantation
Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients
An evaluation of the effects of genetically determined variant metabolizing and transporting proteins involved in the disposition of the immunosuppressive drug tacrolimus in renal transplant recipients.
- Trial name
- NCT00411944
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- KU Leuven
Liver Transplant, Kidney Transplant
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
The purpose of this study is to evaluate the impact of Advagraf, prolonged-release, once daily tacrolimus formulation, on long-term graft survival in kidney and liver allograft recipients.
- Trial name
- ADDRESS (NCT02057484)
- Testing
- Tacrolimus
- Where
- 145 sites in Austria, Belarus and 22 more
- Volunteers
- 2,300 people
- Sponsor
- Astellas Pharma Europe Ltd.
Heart Transplantation
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
This study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function.
- Trial name
- NCT02554955
- Testing
- Daclizumab, Mycophenolate mofetil, Silrolimus
- Where
- 14 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Kidney Transplantation
Islet Transplantation in Type 1 Diabetic Recipients of Kidney Transplants
Study hypothesis is that we can reproduce results of islet transplantation in type one diabetics in patients with a kidney transplant.
- Trial name
- NCT00288977
- Testing
- Islet Infusion
- Volunteers
- 8 people
- Sponsor
- Beth Israel Deaconess Medical Center
Renal Transplantation
Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes
reduce of immunsupression or introduce tolerance with so called TAIZ-monocytes in renal transplant patients
- Trial name
- NCT00223067
- Testing
- TAIZ
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Schleswig-Holstein
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN)
Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients
Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term.
- Conditions
- Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
- Trial name
- Mini-Kidney (NCT01531257)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Kidney Failure
Prospective Study of Urinary Markers of Fibrosis in Kidney Transplants
The purpose of this study is to determine whether urinary connective tissue growth factor (uCTGF) can predict the onset of fibrosis in transplanted kidneys.
- Trial name
- NCT01982903
- Where
- Belgium
- Volunteers
- 180 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
End Stage Renal Disease
CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients
The objective of this study is to determine the extent and magnitude of the pharmacokinetic drug interaction between mycophenolate mofetil (MFF) (under Css conditions) in the presence of iron in renal transplant recipients.
- Trial name
- NCT00227045
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Kidney Transplantation
Observation Study for Prediction of Allograft Survival and Impact of Imaging in Kidney Transplant Recipients.
To further develop personalized medicine in kidney transplantation and improve transplant patient outcomes, attention has been given to define early surrogate endpoints that might aid therapeutic interventions, and help clinical…
- Trial name
- NCT03764124
- Testing
- PET/CT imaging
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- University of Liege
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Renal Transplantation
TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)
Induce tolerance or reduce the amount of immunosuppression after renal transplant patient (receiving cadaver kidney)with so called TAIZ-monocytes
- Trial name
- NCT00223093
- Testing
- TAIZ
- Volunteers
- 10 people
- Sponsor
- University Hospital Schleswig-Holstein
End-stage Chronic Renal Disease, Severe Acute Kidney Failure
Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN)
Renal transplantation is characterized by ischemia-reperfusion lesions in allograft. In a previous study, Julier and al. (Anesthesiology 2003) have demonstrated that sevoflurane reduces glomerular lesions in kidney of patients…
- Conditions
- End-stage Chronic Renal Disease, Severe Acute Kidney Failure, Renal Transplantation
- Trial name
- SévoRein (NCT00337051)
- Testing
- Sevoflurane, Propofol
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Bordeaux
Kidney Transplant; Complications
Esomeprazole or Pantoprazole in Renal Transplantation
prospective, parallel, open-label clinical trial was performed on forty-seven adult renal transplant recipients receiving immunosuppressive therapy with CsA doses adjusted to attain trough concentrations of 100-150 μg/L…
- Trial name
- NCT03812419
- Testing
- Esomeprazole 40 mg, Pantoprazole 40mg
- Volunteers
- 47 people
- Sponsor
- Future University in Egypt
Kidney Transplant, Kidney Transplant Failure
Dapagliflozin in Living-Donor Kidney Transplant Recipients
This randomized, open-label, single-center clinical trial aims to evaluate the effect of dapagliflozin on kidney allograft function in adult recipients of a first living-donor kidney transplant.
- Trial name
- DAPA-GRAFT (NCT07555106)
- Testing
- Dapagliflozin (10mg Tab), Standard of Care
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- University of Guadalajara
Kidney Transplantation, Insulin Resistance
Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes
The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.
- Conditions
- Kidney Transplantation, Insulin Resistance, Atherosclerosis
- Trial name
- NCT00598013
- Testing
- Pioglitazone
- Where
- South Korea
- Volunteers
- 83 people
- Sponsor
- Yonsei University
Renal Transplant Rejection
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant.
- Trial name
- NCT00866879
- Testing
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Northwestern University
Cytomegalovirus Infections
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
This is a Phase II, randomized, double-blind, placebo-controlled study designed to assess the safety and clinical activity of multiple intravenous doses of MCMV5322A/MCMV3068A in cytomegalovirus (CMV)-seronegative recipients of a…
- Trial name
- NCT01753167
- Testing
- MCMV3068A, MCMV5322A
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Renal Transplantation
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
- Trial name
- MYFIIRP (NCT00713284)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- California Pacific Medical Center Research Institute
Kidney Transplantation
Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients
The purpose of this study is to investigate safety and tolerability of an immediate conversion from Tacrolimus to everolimus in stable renal allograft recipients.
- Trial name
- HERMES (NCT01269684)
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis Pharmaceuticals